De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

DSpace Repository

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel

Author: Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E. -M; Augustin, D.; Kuemmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Wuerstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H.; Harbeck, N.
Tübinger Autor(en):
Grischke, Eva-Maria
Published in: Annals of Oncology (2017), Bd. 28, H. 11, S. 2768-2772
Verlagsangabe: Oxford Univ Press
Language: English
Full text: http://dx.doi.org/10.1093/annonc/mdx494
ISSN: 1569-8041
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)